Member Info for share12345

Expert raises flag over the 'shaky science' behind Oxford's Covid jab and claims data behind promising vaccine 'was patched together and doesn't include many over-55s'
time for rms to step in

machine mean orders
boom

What a coincidence. #novacyt release details of their new private testing service "Versalab" on the same day UK Government announces Test to Release: England introduces testing strategy for international arrivals https://gov.uk/government/news/test-to-release-england-introduces-testing-strategy-for-international-arrivals #NCYT #alnov

23 November 2020 07:59

Nov 23 (Reuters) – Avacta Group PLC :
Avacta Group Plc - Sars-cov-2 Rapid Antigen Test Update
Avacta Group Plc - We Remain On Track To Submit Uk Regulatory Application, Or Cta, For Ava6000 Pro-doxorubicin Before End Of Year

Source text for Eikon: Further company coverage: AVTG.L

(Reuters.Briefs@thomsonreuters.com;)

back up to 3p soon

this sp would be 30% down now .if it was that bad ?

people sold out to soon
next /nt to buy ..

n t to buy

buys are come in
rns maybe monday

5m aweek

in September, RMS said it expects substantial revenues to be generated by Pharm 2 Farm from the sale of anti-viral face masks.

Trevor Brown, chief executive, said: ”Since we announced the proposed acquisition, the market for Pharm 2 Farm products, in particular for face masks, has continued to grow exponentially.

P2F is setting up a production line that will be able to produce up to 5mln standard or anti-viral face masks per month.

“The successful development of a face mask with anti-viral properties will, we believe, generate substantial revenue for the enlarged group," said Brown.

“Proof of Concept for the efficacy of the anti-viral mask is imminent and mask production is anticipated to commence in the first quarter of 2021".

Elsewhere, RMS said Cloudveil is currently negotiating with a London-based law firm over a security programme and had also bid for a testing contract for one of the UK’s largest public sector financial services institutions.

Gyrometric, meanwhile, is set to start a three-month trial at a Tarmac cement manufacturing operation now that a site has become available.

Elsewhere, RMS said Cloudveil is currently negotiating with a London-based law firm over a security programme and had also bid for a testing contract for one of the UK’s largest public sector financial services institutions.

Gyrometric, meanwhile, is set to start a three-month trial at a Tarmac cement manufacturing operation now that a site has become available.

Remote Monitored Systems PLC (LON:RMS), formerly known as Strat Aero, has two main investments: Gyrometric and CloudVeil.

Gyrometric provides a way remotely monitor rotating shafts such as those used in wind turbines, ships and manufacturing operations to minimise downtime.

CloudVeil is a security and risk management consultancy in teh early stages of its development.

Remote Monitored Systems sees big opportunity with P2F acquisition
Snapshot

RMS core business is GyroMetric, which remotely monitors rotating shafts
Diversified by acquiring surveillance and risk management startup Cloudveil
Set to buy Pharm 2 Farm and make anti-viral face masks

London midday: Stocks in the red as virus fears weigh

Thu, 19th Nov 2020 10:55
ShareCast

(Sharecast News) - London stocks were still weaker by midday on Thursday as optimism over a potential Covid-19 vaccine was replaced by worries about rising cases, tightening restrictions and their impact on the economy.
The FTSE 100 was down 0.9% at 6,325.83.

IG said: "Virus fears have hit an overextended global stock market this morning, knocking European equities sharply lower and pointing towards a weaker start in the US. After the soar-away gains of the past two weeks, equities now look much more richly-valued, and thus vulnerable to an outbreak of bad news.

"This is precisely what we got in the form of spreading infections in the US but also in Japan, a worrying sign indeed for a country that had been successful earlier in the year in controlling the spread. Even reports of success for AstraZeneca's new vaccine were not enough, the impact of these vaccine announcements having been on a declining trend since the first, excitedly-received news from Pfizer almost three weeks ago.

Dr. Krutika Kuppalli, infectious disease researcher

“For the first time, I have hope. Interim vaccine data show more than 90% efficacy, as much as measles. By next winter, we will be getting back to normal. By 2022, we will start to socialize. We can’t eradicate COVID-19 but can eliminate it, perhaps by 2023.”

Dr Gareth Cave is a University Lecturer at Nottingham Trent University, who has invented a face mask that is “more than 90% effective at killing coronavirus.

The anti-viral face-covering features a fluid-repellent outer layer which reduces the inhalation of droplets that carry Covid-19.

There is also a copper lining embedded in the mask which releases ions which kill the virus if they come into contact with it.

Tests have shown that the masks kills more than 90% of flu and coronavirus infections.

Gareth says the new masks are due to go into production in Nottingham in late November and he hopes for them to be commercially available from December.

They will initially be available for healthcare, transport and foodservice settings.

Lockdowns in Europe avoidable, vaccines 'not a silver bullet': WHO Europe http://reut.rs/2UIHYVG

whats one of the best platform for research